Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis (Q83095059)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 April 2006

Language	Label	Description	Also known as
English	Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis	scientific article published on 05 April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Rocchi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

S Verma

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

5 April 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Supportive Care in Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

917-927

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

https://scigraph.springernature.com/pub.10.1007/s00520-006-0035-8

0 references

Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of locoregional recurrent breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimates of the lifetime costs of breast cancer treatment in Canada.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Local-regional breast cancer recurrence following mastectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic implications of hip fracture: health service use, institutional care and cost in Canada.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Annual hazard rates of recurrence for breast cancer after primary therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16596419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-006-0035-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596419%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83095059&oldid=1962253032"